中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

6 records (took 0.022 seconds)

    IMMUNOGLOBULIN G-BINDING PEPTIDE
    1.
    发明申请
    IMMUNOGLOBULIN G-BINDING PEPTIDE 审中-公开

    公开(公告)号：US20180044401A1

    公开(公告)日：2018-02-15

    申请号：US15501320

    申请日：2015-08-27

    Applicant: KANEKA CORPORATION

    Inventor： Shinichi YOSHIDA ,  Dai MURATA

    IPC: C07K14/735

    CPC classification number: C07K14/70535 ,  C07K16/00 ,  C07K2317/55

    Abstract: The objective of the present invention is to provide a peptide of which both of binding forces to a Fc region and a Fab region are superior. In addition, the objective of the present invention is to provide a DNA which encodes the peptide, a vector which contains the DNA, and a transformant which is transformed by the vector. The problem can be solved by providing the peptide having the specific sequence.

    DISSOCIATION CAPACITY-BOOSTED LIGAND FOR AFFINITY DISSOCIATION MATRIX
    3.
    发明申请
    DISSOCIATION CAPACITY-BOOSTED LIGAND FOR AFFINITY DISSOCIATION MATRIX 审中-公开
    分散能力提升的配偶关系

    公开(公告)号：US20160215026A1

    公开(公告)日：2016-07-28

    申请号：US14916263

    申请日：2014-09-05

    Applicant: KANEKA CORPORATION

    Inventor： Shinichi YOSHIDA ,  Kanji OSHIMA ,  Kazunobu MINAKUCHI

    IPC: C07K14/31 ,  C07K16/00 ,  C07K1/22

    CPC classification number: C07K14/31 ,  C07K1/22 ,  C07K16/00

    Abstract: The present invention produces affinity ligands that make it possible to increase the purity of antibodies themselves, which is the main purpose of affinity purification, and, further, to improve the selectivity for antibody monomers and thereby reduce the load of removing antibody multimers on downstream purification steps. The present invention provides new affinity ligands which are modified proteins obtained by introducing a mutation into a protein to increase the number of acidic amino acids in the amino acid sequence of the protein; methods for designing the modified proteins; methods for producing the modified proteins; and affinity separation matrices containing the modified proteins as ligands immobilized therein.

    Abstract translation: 本发明产生亲和配体，其可以提高抗体本身的纯度，这是亲和纯化的主要目的，此外，为了提高抗体单体的选择性，从而降低了下游纯化中除去抗体多聚体的负荷 脚步。 本发明提供了新的亲和配体，其是通过向蛋白质中引入突变而增加蛋白质的氨基酸序列中酸性氨基酸数目而获得的修饰蛋白质; 设计修饰蛋白的方法 生产修饰蛋白的方法; 和含有修饰蛋白质的亲和力分离基质作为其中固定的配体。

    Fab REGION-BINDING PEPTIDE
    5.
    发明申请
    Fab REGION-BINDING PEPTIDE 审中-公开
    Fab区域结合肽

    公开(公告)号：US20160289306A1

    公开(公告)日：2016-10-06

    申请号：US14914439

    申请日：2014-08-28

    Applicant: KANEKA CORPORATION

    Inventor： Shinichi YOSHIDA ,  Dai MURATA

    IPC: C07K16/12 ,  C07K14/315 ,  C07K1/22

    CPC classification number: C07K16/1275 ,  C07K1/22 ,  C07K14/315 ,  C07K2317/55 ,  C12N2510/02

    Abstract: An object of the present invention is to provide a Fab region-binding peptide having an excellent ability for binding to a Fab region of IgG, an affinity separation matrix having the peptide as a ligand, and a method for producing a Fab region-containing protein, the method using the affinity separation matrix. Further, another object of the present invention is to provide a DNA encoding for the peptide, a vector containing the DNA, and a transformant which has been transformed by the vector. The Fab region-binding peptide according to the present invention is characterized in having a mutation at a specific site in comparison with wild-type SpG-β1.

    Abstract translation: 本发明的目的是提供具有优异的结合IgG Fab区域的Fab区域结合肽，具有该肽作为配体的亲和力分离基质，以及制备含有Fab区域的蛋白质的方法 ，使用亲和力分离矩阵的方法。 此外，本发明的另一个目的是提供编码肽的DNA，含有DNA的载体和已经通过载体转化的转化体。 与野生型SpG-β1相比，本发明的Fab区结合肽的特征在于在特定部位具有突变。

    IMMUNOGLOBULIN-BINDING PEPTIDE WITH IMPROVED STABILITY
    6.
    发明申请
    IMMUNOGLOBULIN-BINDING PEPTIDE WITH IMPROVED STABILITY 审中-公开

    公开(公告)号：US20200031915A1

    公开(公告)日：2020-01-30

    申请号：US16585895

    申请日：2019-09-27

    Applicant: KANEKA CORPORATION

    Inventor： Shinichi YOSHIDA

    IPC: C07K16/18 ,  C07K1/22

    Abstract: An altered immunoglobulin-binding peptide includes an amino acid sequence. The amino acid sequence may be a first amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 5, wherein an amino acid residue at the 8th position is substituted by Asp, Glu, His, Ile, Lys, Leu or Val. The amino acid sequence may be a second amino acid sequence further comprising at least one deletion, substitution and/or addition in the first amino acid sequence at one or more positions other than the 8th position. The amino acid sequence may be a third amino acid sequence having a sequence identity of 80% or more with the first amino acid sequence, provided that the amino acid substitution at the 8th position is not further mutated.

Patent Agency Ranking